-
1
-
-
1942542429
-
Age-related macular degeneration is the leading cause of blindness
-
N.M. Bressler Age-related macular degeneration is the leading cause of blindness JAMA 291 2004 1900 1901
-
(2004)
JAMA
, vol.291
, pp. 1900-1901
-
-
Bressler, N.M.1
-
2
-
-
37449010146
-
The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis
-
T.Y. Wong, U. Chakravarthy, and R. Klein The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 2008 116 126
-
(2008)
Ophthalmology
, vol.115
, pp. 116-126
-
-
Wong, T.Y.1
Chakravarthy, U.2
Klein, R.3
-
3
-
-
84856002562
-
Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010
-
S.B. Bloch, M. Larsen, and I.C. Munch Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010 Am J Ophthalmol 153 2012 209 213
-
(2012)
Am J Ophthalmol
, vol.153
, pp. 209-213
-
-
Bloch, S.B.1
Larsen, M.2
Munch, I.C.3
-
4
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
MARINA Study Group
-
P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
-
(2006)
N Engl J Med
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
-
5
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
ANCHOR Study Group
-
D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
-
(2006)
N Engl J Med
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
-
6
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
7
-
-
79955085045
-
Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 Medicare fee-for-service part B claims file
-
R.J. Brechner, P.J. Rosenfeld, J.D. Babish, and S. Caplan Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file Am J Ophthalmol 151 2011 887 895
-
(2011)
Am J Ophthalmol
, vol.151
, pp. 887-895
-
-
Brechner, R.J.1
Rosenfeld, P.J.2
Babish, J.D.3
Caplan, S.4
-
8
-
-
58949093226
-
Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: Results of the Pan-American Collaborative Retina Study Group at 12 months follow-up
-
J.F. Arevalo, J. Fromow-Guerra, and J.G. Sanchez Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up Retina 28 2008 1387 1394
-
(2008)
Retina
, vol.28
, pp. 1387-1394
-
-
Arevalo, J.F.1
Fromow-Guerra, J.2
Sanchez, J.G.3
-
9
-
-
84858139464
-
Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model
-
J.J. Patel, M.A. Mendes, and M. Bounthavong Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model J Eval Clin Pract 18 2012 247 255
-
(2012)
J Eval Clin Pract
, vol.18
, pp. 247-255
-
-
Patel, J.J.1
Mendes, M.A.2
Bounthavong, M.3
-
10
-
-
61349102385
-
Economic implications of current age-related macular degeneration treatments
-
W.E. Smiddy Economic implications of current age-related macular degeneration treatments Ophthalmology 116 2009 481 487
-
(2009)
Ophthalmology
, vol.116
, pp. 481-487
-
-
Smiddy, W.E.1
-
11
-
-
84863327423
-
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
-
IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
-
(2012)
Ophthalmology
, vol.119
, pp. 1399-1411
-
-
Chakravarthy, U.1
Harding, S.P.2
Rogers, C.A.3
-
12
-
-
84875260404
-
Diffusion of technologies for the care of older adults with exudative age-related macular degeneration
-
J.D. Stein, B.W. Hanrahan, G.M. Comer, and F.A. Sloan Diffusion of technologies for the care of older adults with exudative age-related macular degeneration Am J Ophthalmol 155 2013 688 696
-
(2013)
Am J Ophthalmol
, vol.155
, pp. 688-696
-
-
Stein, J.D.1
Hanrahan, B.W.2
Comer, G.M.3
Sloan, F.A.4
-
13
-
-
33644792767
-
Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement
-
CONSORT Group
-
G. Piaggio, D.R. Elbourne, D.G. Altman CONSORT Group Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement JAMA 295 2006 1152 1160
-
(2006)
JAMA
, vol.295
, pp. 1152-1160
-
-
Piaggio, G.1
Elbourne, D.R.2
Altman, D.G.3
-
14
-
-
79956218863
-
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
-
CATT Research Group, D.F. Martin, M.G. Maguire, and G.S. Ying Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
-
(2011)
N Engl J Med
, vol.364
, pp. 1897-1908
-
-
Research Group, C.1
Martin, D.F.2
Maguire, M.G.3
Ying, G.S.4
-
15
-
-
84863320414
-
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
-
(2012)
Ophthalmology
, vol.119
, pp. 1388-1398
-
-
Martin, D.F.1
Maguire, M.G.2
Fine, S.L.3
-
16
-
-
84874654113
-
A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
-
MANTA Research Group
-
I. Krebs, L. Schmetterer, A. Boltz MANTA Research Group A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Br J Ophthalmol 97 2013 266 271
-
(2013)
Br J Ophthalmol
, vol.97
, pp. 266-271
-
-
Krebs, I.1
Schmetterer, L.2
Boltz, A.3
-
17
-
-
84872026174
-
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
-
Comparison of Age-related Macular Degeneration Treatments Trials Research Group
-
G.S. Ying, J. Huang, M.G. Maguire Comparison of Age-related Macular Degeneration Treatments Trials Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
-
(2013)
Ophthalmology
, vol.120
, pp. 122-129
-
-
Ying, G.S.1
Huang, J.2
Maguire, M.G.3
-
18
-
-
84874948393
-
Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The LUMIERE study
-
LUMIERE Study Group
-
S.Y. Cohen, G. Mimoun, H. Oubraham LUMIERE Study Group Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study Retina 33 2013 474 481
-
(2013)
Retina
, vol.33
, pp. 474-481
-
-
Cohen, S.Y.1
Mimoun, G.2
Oubraham, H.3
-
19
-
-
53449093792
-
Intersession repeatability of visual acuity scores in age-related macular degeneration
-
P.J. Patel, F.K. Chen, G.S. Rubin, and A. Tufail Intersession repeatability of visual acuity scores in age-related macular degeneration Invest Ophthalmol Vis Sci 49 2008 4347 4352
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 4347-4352
-
-
Patel, P.J.1
Chen, F.K.2
Rubin, G.S.3
Tufail, A.4
-
20
-
-
84856344197
-
Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: Implications for sensitivity and specificity
-
N. Shah, D.A. Laidlaw, and S.P. Shah Computerized repeating and averaging improve the test-retest variability of ETDRS visual acuity measurements: implications for sensitivity and specificity Invest Ophthalmol Vis Sci 52 2011 9397 9402
-
(2011)
Invest Ophthalmol Vis Sci
, vol.52
, pp. 9397-9402
-
-
Shah, N.1
Laidlaw, D.A.2
Shah, S.P.3
-
21
-
-
69249213449
-
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration
-
H. Dadgostar, A.A. Ventura, and J.Y. Chung Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 2009 1740 1747
-
(2009)
Ophthalmology
, vol.116
, pp. 1740-1747
-
-
Dadgostar, H.1
Ventura, A.A.2
Chung, J.Y.3
-
22
-
-
79955066891
-
Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies
-
C.A. McCannel Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies Retina 31 2011 654 661
-
(2011)
Retina
, vol.31
, pp. 654-661
-
-
McCannel, C.A.1
-
23
-
-
84862907626
-
An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab
-
R.A. Goldberg, H.W. Flynn Jr., and R.F. Isom An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab Am J Ophthalmol 153 2012 204 208
-
(2012)
Am J Ophthalmol
, vol.153
, pp. 204-208
-
-
Goldberg, R.A.1
Flynn Jr., H.W.2
Isom, R.F.3
|